Relative resistance of HIV-1 founder viruses to control by interferon-alpha

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Fenton May, Angharad E ^a   Dibben, Oliver ^a   Emmerich, Tanja ^a   Ding, Haitao ^b   Pfafferott, Katja ^a   Aasa Chapman, Marlen M ^c   Pellegrino, Pierre ^d   Williams, Ian ^d   Cohen, Myron S ^e   Gao, Feng ^f   Shaw, George M ^g   Hahn, Beatrice H ^g   Ochsenbauer, Christina ^b   Kappes, John C ^b,h   Borrow, Persephone ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Acute infection; Founder virus; Human immunodeficiency virus type 1; Type 1 interferon; Viral inhibition

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BETA INTERFERON;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; FOUNDER EFFECT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; UPREGULATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

HARNESS; HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; MICROBIAL SENSITIVITY TESTS; VIRUS REPLICATION;

EID: 84888776867     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-146     Document Type: Article

References (102)

1. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223. 10.1038/nature08757, 20220840.
2. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557. 10.1073/pnas.0802203105, 2387184, 18490657.
3. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009, 83:3556-3567. 10.1128/JVI.02132-08, 2663249, 19193811.
4. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23. 10.1038/nri2674, 3119211, 20010788.
5. Borrow P. Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS 2011, 6:353-363. 10.1097/COH.0b013e3283495996, 3266478, 21734567.
6. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264. 10.1146/annurev.biochem.67.1.227, 9759489.
7. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998, 95:5623-5628.
8. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381. 10.1016/j.immuni.2006.08.007, 16979569.
9. Gale MJ, Sen GC. Viral evasion of the interferon system. J Interferon Cytokine Res 2009, 29:475-476. 10.1089/jir.2009.0078, 3016867, 19694549.
10. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47. 10.1099/vir.0.83391-0, 18089727.
11. Taylor KE, Mossman KL. Recent advances in understanding viral evasion of type I interferon. Immunology 2013, 138:190-197. 10.1111/imm.12038, 23173987.
12. Gresser I, Tovey MG, Maury C, Bandu MT. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum: II: Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J Exp Med 1976, 144:1316-1323. 10.1084/jem.144.5.1316, 2190450, 186555.
13. Muller U, Steinhoff U, Reis LFL, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921. 10.1126/science.8009221, 8009221.
14. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211. 10.1126/science.1235214, 3640797, 23580529.
15. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207. 10.1126/science.1235208, 23580528.
16. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038. 10.1038/nature07831, 2785041, 19262509.
17. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005, 79:12164-12172. 10.1128/JVI.79.19.12164-12172.2005, 1211549, 16160143.
18. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733. 10.1128/JVI.01844-08, 2663284, 19176632.
19. Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, Dibben O, Stacey A, Fellay J, Shianna KV, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010, 116:3839-3852. 10.1182/blood-2010-03-273763, 2981539, 20693428.
20. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, Perie L, Brochard P, Delache B, Calvo J, Andrieu T, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008, 112:4598-4608. 10.1182/blood-2008-06-162651, 18787223.
21. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch MS. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1985, 1:602-604.
22. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 1986, 6:143-152. 10.1089/jir.1986.6.143, 2425014.
23. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS. Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 1990, 145:2669-2676.
24. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994, 24:205-219. 10.1016/0166-3542(94)90068-X, 7526792.
25. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650. 10.1038/nature00939, 12167863.
26. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006, 203:41-46. 10.1084/jem.20051512, 2118075, 16418394.
27. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006, 80:7645-7657. 10.1128/JVI.00206-06, 1563726, 16840343.
28. Battivelli E, Lecossier D, Matsuoka S, Migraine J, Clavel F, Hance AJ. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol 2010, 84:11010-11019. 10.1128/JVI.00758-10, 2953162, 20702630.
29. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853. 10.1038/nature02343, 14985764.
30. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
31. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
32. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE, Landry S, Pan T, Weitzman MD, David M. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012, 491:125-128. 10.1038/nature11433, 3705913, 23000900.
33. Maitra RK, McMillan NA, Desai S, McSwiggen J, Hovanessian AG, Sen G, Williams BR, Silverman RH. HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology 1994, 204:823-827. 10.1006/viro.1994.1601, 7524241.
34. Sanghvi VR, Steel LF. The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol 2011, 85:12614-12621. 10.1128/JVI.05240-11, 3209364, 21937648.
35. Lu J, Pan Q, Rong L, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol 2011, 85:2126-2137. 10.1128/JVI.01531-10, 3067758, 21177806.
36. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485. 10.1038/nature09907, 3409588, 21478870.
37. Pincetic A, Kuang Z, Seo EJ, Leis J. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol 2010, 84:4725-4736. 10.1128/JVI.02478-09, 2863725, 20164219.
38. Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksler G, Meltzer MS, Dieffenbach C. A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med 1990, 172:1433-1442. 10.1084/jem.172.5.1433, 2188659, 2264889.
39. Geiss GK, Bumgarner RE, An MC, Agy MB, t'Wout AB, Hammersmark E, Carter VS, Upchurch D, Mullins JI, Katze MG. Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology 2000, 266:8-16. 10.1006/viro.1999.0044, 10612655.
40. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010, 11:1005-1013. 10.1038/ni.1941, 2958248, 20871604.
41. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol 2011, 85:1224-1236. 10.1128/JVI.01635-10, 3020501, 21084468.
42. Doehle BP, Chang K, Rustagi A, McNevin J, McElrath MJ, Gale M. Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol 2012, 86:8367-8374. 10.1128/JVI.00423-12, 3421752, 22593165.
43. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009, 83:10395-10405. 10.1128/JVI.00849-09, 2753137, 19706707.
44. Hotter D, Kirchhoff F, Sauter D. HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 2013, 87:7160-7165. 10.1128/JVI.00526-13, 3676088, 23552418.
45. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005, 115:3265-3275. 10.1172/JCI26032, 1253628, 16224540.
46. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, Chaperot L, Plumas J, Randall RE, Si-Tahar M, et al. Innate Sensing of HIV-Infected Cells. PLoS Pathog 2011, 7:e1001284. 10.1371/journal.ppat.1001284, 3040675, 21379343.
47. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009, 364:675-687. 10.1098/rstb.2008.0185, 2660912, 19038776.
48. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010, 6:e1000856. 10.1371/journal.ppat.1000856, 2851737, 20386718.
49. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009, 5:e1000574. 10.1371/journal.ppat.1000574, 2729927, 19730691.
50. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010, 7:51. 10.1186/1742-4690-7-51, 2890665, 20529266.
51. Roy S, Katze MG, Parkin NT, Edery I, Hovanessian AG, Sonenberg N. Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. Science 1990, 247:1216-1219. 10.1126/science.2180064, 2180064.
52. Schroder HC, Ugarkovic D, Wenger R, Reuter P, Okamoto T, Muller WE. Binding of Tat protein to TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2'-5')oligoadenylate synthetase. AIDS Res Hum Retroviruses 1990, 6:659-672. 10.1089/aid.1990.6.659, 1694453.
53. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010, 201:1686-1696. 10.1086/652420, 2946345, 20420510.
54. Boue F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, Goujard C, Lancar R, Costagliola D. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 2011, 25:115-118. 10.1097/QAD.0b013e328340a1e7, 20962614.
55. Hatzakis A, Gargalianos P, Kiosses V, Lazanas M, Sypsa V, Anastassopoulou C, Vigklis V, Sambatakou H, Botsi C, Paraskevis D, Stalgis C. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001, 21:861-869. 10.1089/107999001753238114, 11710999.
56. Skillman DR, Malone JL, Decker CF, Wagner KF, Mapou RL, Liao MJ, Testa D, Meltzer MS. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. J Infect Dis 1996, 173:1107-1114. 10.1093/infdis/173.5.1107, 8627061.
57. Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, et al. Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res 2010, 30:461-464. 10.1089/jir.2009.0090, 2964361, 20235638.
58. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013, 207:213-222. 10.1093/infdis/jis663, 23105144.
59. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 2010, 107:9843-9848. 10.1073/pnas.0911932107, 2906837, 20457926.
60. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 2005, 79:14355-14370. 10.1128/JVI.79.22.14355-14370.2005, 1280235, 16254370.
61. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211. 10.1038/nm0297-205, 9018240.
62. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
63. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006, 26:1888-1897. 10.1128/MCB.26.5.1888-1897.2006, 1430259, 16479007.
64. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007, 366:525-539. 10.1016/j.jmb.2006.11.053, 17174979.
65. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947. 10.1126/science.1143767, 1991296, 17641165.
66. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879. 10.1097/00002030-200309050-00005, 12960819.
67. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289. 10.1084/jem.20090378, 2715054, 19487424.
68. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012, 86:2715-2728. 10.1128/JVI.06157-11, 3302286, 22190722.
69. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr JL, Soderberg KA, Weinhold KJ, Cunningham CK, et al. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol 2012, 86:6835-6846. 10.1128/JVI.00437-12, 3393529, 22514337.
70. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013, 110:6626-6633. 10.1073/pnas.1304288110, 3637789, 23542380.
71. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991, 7:375-380. 10.1089/aid.1991.7.375, 1906289.
72. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862. 10.1126/science.273.5283.1856, 8791590.
73. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 5:e1000791. 10.1371/journal.pgen.1000791, 2791220, 20041166.
74. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
75. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725. 10.1038/382722a0, 8751444.
76. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997, 277:959-965. 10.1126/science.277.5328.959, 9252328.
77. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity 2012, 37:426-440. 10.1016/j.immuni.2012.09.005, 22999948.
78. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 2010, 84:7581-7591. 10.1128/JVI.00286-10, 2897600, 20504921.
79. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice HA, Yue L, Vishwanathan SA, Kilembe W, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog 2012, 8:e1003041. 10.1371/journal.ppat.1003041, 3510241, 23209412.
80. Zaunders J, Dyer WB, Churchill M. The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control. Curr Opin HIV AIDS 2011, 6:151-156. 10.1097/COH.0b013e3283454d5b, 21378562.
81. Kunzi MS, Farzadegan H, Margolick JB, Vlahov D, Pitha PM. Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression. J Infect Dis 1995, 171:822-828. 10.1093/infdis/171.4.822, 7706808.
82. Edlin BR. St Clair MH, Pitha PM, Whaling SM, King DM, Bitran JD, Weinstein RA: In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med 1992, 117:457-460. 10.7326/0003-4819-117-6-457, 1503348.
83. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010, 6:e1000890. 10.1371/journal.ppat.1000890, 2869329, 20485520.
84. Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 2013, 123:380-393. 3533301, 23221345.
85. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012, 8:e1002721. 10.1371/journal.ppat.1002721, 3364956, 22693447.
86. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253-1272. 10.1084/jem.20090365, 2715063, 19487423.
87. Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK, et al. Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 2012, 9:89. 10.1186/1742-4690-9-89, 3496648, 23110705.
88. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. Natural variation in Vif: differential impact on APOBEC3G/3 F and a potential role in HIV-1 diversification. PLoS Pathog 2005, 1:e6. 10.1371/journal.ppat.0010006, 1238741, 16201018.
89. Ravimohan S, Gama L, Barber SA, Clements JE. Regulation of SIV mac 239 basal long terminal repeat activity and viral replication in macrophages: functional roles of two CCAAT/enhancer-binding protein beta sites in activation and interferon beta-mediated suppression. J Biol Chem 2010, 285:2258-2273. 10.1074/jbc.M109.075929, 2807283, 19933495.
90. Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, Douek DC, Silvestri G, Muller-Trutwin M, Vasile-Pandrea I, Apetrei C, et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol 2010, 84:7886-7891. 10.1128/JVI.02612-09, 2897601, 20484518.
91. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009, 5:e1000296. 10.1371/journal.ppat.1000296, 2633618, 19214219.
92. Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS, Haase AT. Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J Immunol 2009, 183:1975-1982. 10.4049/jimmunol.0803222, 3552354, 19596987.
93. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L. Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 2010, 24:1415-1423. 10.1097/QAD.0b013e32833ac623, 2991092, 20495440.
94. Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, Peng J, Tang Y, Brumme ZL, Heckerman D, Schneidewind A, Allen TM. Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B gag proteins. J Virol 2013, 87:3952-3965. 10.1128/JVI.03233-12, 3624202, 23365420.
95. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, et al. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010, 84:11937-11949. 10.1128/JVI.01086-10, 2977869, 20810731.
96. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80:3617-3623. 10.1128/JVI.80.7.3617-3623.2006, 1440414, 16537629.
97. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H, Avila S, Lobritz MA, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009, 5:e1000365. 10.1371/journal.ppat.1000365, 2659432, 19343217.
98. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009, 83:9474-9485. 10.1128/JVI.01089-09, 2738220, 19587057.
99. O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, Rolnitzky L, Markowitz M, Margolis DM, Levy D, Bhardwaj N. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J Clin Invest 2011, 121:1088-1101. 10.1172/JCI44960, 3049388, 21339641.
100. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008, 47:385-395.
101. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, Chemin I. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011, 6:e26315. 10.1371/journal.pone.0026315, 3201951, 22046272.
102. Wang Y, Bergmeier LA, Stebbings R, Seidl T, Whittall T, Singh M, Berry N, Almond N, Lehner T. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 2009, 27:870-881. 10.1016/j.vaccine.2008.11.084, 2744409, 19084567.